Intangible Assets

3 Months Ended

Mar. 31, 2022

Intangible Assets, Net (Excluding Goodwill) [Abstract]

6. Intangible Assets

Acquired Intangible Assets

The following tables present details of the Company’s acquired finite-lived intangible assets as of March 31, 2022 and December 31, 2021 (in thousands, except weighted-average amortization period):


As of March 31, 2022	Weighted-Average Amortization Period	Gross Carrying Amount		Accumulated Amortization		Net
Finite-lived intangible assets:
Developed technology	8.8 years	$	62,466	$	(3,570)	$	58,896
Customer relationships	15.0 years	$	6,626	$	(2,099)	$	4,527
Trade secrets and processes	20.0 years	5,256		(1,117)		4,139
Other	5.0 years	1,709		(1,622)		87
Total intangible assets subject to amortization	9.8 years	$	76,057	$	(8,408)	$	67,649
Indefinite-lived intangible assets:
In-process research and development		$	20,823	$	—	$	20,823
Total intangible assets		$	96,880	$	(8,408)	$	88,472


As of December 31, 2021	Weighted-Average Amortization Period	Gross Carrying Amount		Accumulated Amortization		Net
Finite-lived intangible assets:
Developed technology	8.8 years	$	62,466	$	(1,784)	$	60,682
Customer relationships	15.0 years	$	6,762	$	(2,029)	$	4,733
Trade secrets and processes	20.0 years	5,256		(1,051)		4,205
Other	5.0 years	1,744		(1,569)		175
Total intangible assets subject to amortization	9.8 years	$	76,228	$	(6,433)	$	69,795
Indefinite-lived intangible assets:
In-process research and development		20,823		—		20,823
Total intangible assets		$	97,051	$	(6,433)	$	90,618

The customer relationships and intangible assets classified as “Other” subject to amortization relate to the acquisition of Crossmed S.p.A., the Company’s wholly-owned subsidiary in Italy, during the third quarter of 2017. The gross carrying amount and accumulated amortization of these intangible assets are subject to foreign currency translation effects.

The Company reviews indefinite-lived intangible assets for impairment annually during the fourth quarter or more frequently if events or circumstances indicate that an impairment loss may have occurred. The Company determined that there were no impairment indicators as of March 31, 2022.

The following table presents the amortization expense recorded related to the Company’s finite-lived intangible assets for the three months ended March 31, 2022 and 2021 (in thousands):


	Three Months Ended March 31,
	2022		2021
Cost of revenue	$	66	$	66

Sales, general and administrative	1,982		212
Total	$	2,048	$	278